` GNFT (Genfit SA) vs DAX Index Comparison - Alpha Spread

GNFT
vs
DAX Index

Over the past 12 months, GNFT has underperformed DAX Index, delivering a return of -20% compared to the DAX Index's 30% growth.

Stocks Performance
GNFT vs DAX Index

Loading
GNFT
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
GNFT vs DAX Index

Loading
GNFT
DAX Index
Difference
www.alphaspread.com

Performance By Year
GNFT vs DAX Index

Loading
GNFT
DAX Index
Add Stock

Competitors Performance
Genfit SA vs Peers

DAX Index
GNFT
ABBV
AMGN
GILD
VRTX
Add Stock

Genfit SA
Glance View

Market Cap
192.6m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
7.855 EUR
Undervaluation 51%
Intrinsic Value
Price
G
Back to Top